---
layout: post
title: "【图解季报】羚锐制药：2022年一季度归母净利润同比增长35.4%，约为1.3亿元"
date: 2022-04-25 20:10:15 +0800
categories: dongfangcaifuChoiceshuju
tags: 东方财富Choice数据新闻
---
<p>羚锐制药于2022年4月26日披露一季报，公司2022年一季度实现营业总收入6.8亿，同比增长15.7%；实现归母净利润1.3亿，同比增长35.4%；每股收益为0.24元。</p><img id="image7" class="autoimg" src="https://dfscdn.dfcfw.com/download/D240CBE4715CB5E2AD8FE2806ED95B10BF_w800h400.jpg" alt=""><p style="color:#61768C;font-size:0.9em;"></p><img id="image9" class="autoimg" src="https://dfscdn.dfcfw.com/download/D232A74A58B72C8675754A0B71AF1E6157_w800h400.jpg" alt=""><p><strong>经营性现金流大幅下降</strong></p><p>公司2022一季度营业成本1.7亿，同比增长29.3%，高于营业收入15.7%的增速，导致毛利率下降2.6%。期间费用率为56.7%，较去年下降0.8个百分点。经营性现金流大幅下降61.7%至8635.9万。</p><img id="image12" class="autoimg" src="https://dfscdn.dfcfw.com/download/D287BF7369F795BB52FD1D2B2D0E6E2DF9_w800h400.jpg" alt=""><p style="font-weight:bold;"></p><p style="margin: 10px 0; color: #999">免责声明：本文基于大数据生产，仅供参考，不构成任何投资建议，据此操作风险自担。</p><style>.autoimg {display: block;border: 0;max-width: 100%;margin: 0 auto;} .tbl {border-collapse: collapse;border-spacing: 0;text-align: center;width: 100% !important;} .tbl tr th, .tbl tr td {border: 1px solid #d8e6ff;padding: 5px;text-align: center;} .tbl tr th {color: #fff;background-color: #1c65b0;vertical-align: middle;} .tbl tr td {color: #000;background-color: #fff;} .imgtitle {text-indent: 0;text-align: center;color: #2395F1;} .autosrc {color: #999;display: block;text-align: center;margin-bottom: 5px;}</style>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202204252357481736>

[返回东方财富Choice数据新闻](//finews.withounder.com/category/dongfangcaifuChoiceshuju.html)｜[返回首页](//finews.withounder.com/)